Journal
MEDCHEMCOMM
Volume 8, Issue 8, Pages 1659-1667Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c7md00247e
Keywords
-
Funding
- Intramural Research Program of the NIH, National Institute of Diabetes and Digestive and Kidney Diseases
- Inserm, Univ. Lille, France
- UGC, India
- National Heart, Lung, and Blood Institute [R01HL133589]
Ask authors/readers for more resources
A pyrazolo[4,3-e][1,2,4] triazolo[1,5-c] pyrimidin-5-amine antagonist of the A(2A) adenosine receptor (AR) was functionalized as amine congeners, fluorescent conjugates and a sulfonate, and the A(2A)AR binding modes were predicted computationally. The optimal n-butyl spacer was incorporated into the following A(2A)AR-selective (K-i, nM) conjugates: BODIPY630/650 derivative 11 (MRS7396, 24.6) and AlexaFluor488 derivative 12 (MRS7416, 30.3). Flow cytometry of 12 in hA(2A)AR-expressing HEK-293 cells displayed saturable binding (low nonspecific) and inhibition by known A(2A)AR antagonists. Water-soluble sulfonate 13 was a highly potent (K-i = 6.2 nM) and selective A(2A)AR antagonist based on binding and functional assays. Docking and molecular dynamics simulations predicted the regions of interaction of the distal portions of these chain-extended ligands with the A(2A)AR. The BODIPY630/650 fluorophore of 11 was buried in a hydrophobic interhelical (TM1/TM7) region, while AlexaFluor488 of 12 associated with the hydrophilic extracellular loops. In conclusion, we have identified novel high affinity antagonist probes for A(2A)AR drug discovery and characterization.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available